An observational study in Myocardial Infarction, Acute and Coronary Stenosis, sponsored by Seung-Jung Park. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.
Sponsored by Seung-Jung Park · Observational
Among 99 studies in Myocardial Infarction with a site in Korea, Republic of — 21 open to participants now, 26 under way, 5 of them phase 3. Myocardial Infarction · Korea, Republic of.
Among the 99 studies in Myocardial Infarction with a site in Korea, Republic of, this one is the 9th largest by planned enrollment of the 25 observational ones that give a count, is one of 3 that started in 2018, is one of 25 observational ones, reaches primary completion later than 7 of the 25 other live ones, and was the 60th registered.
2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.
Browse Myocardial Infarction studies →21 of the 99 studies in Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Chonnam National University Hospital · Sites in Korea, Republic of
Chonnam National University Hospital · Sites in Korea, Republic of
Chonnam National University Hospital · Sites in Korea, Republic of
CHA University · Sites in Korea, Republic of
Seoul National Hospital · Sites in Korea, Republic of
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 255 Myocardial Infarction studies recruiting now, 172 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 16 take children under 18; 27 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 25 · Phase 4 22
First in 2001; this study’s year is marked. 3 started in 2018.
This study's planned enrollment of 5,000 is above the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 820 across the 73 interventional studies, 1,537 across the 25 observational. Of the 55 that completed or were terminated, 14 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 99 have an industry lead sponsor. The 10 most frequent:
Seung-Jung Park is the lead sponsor of 82 studies on the registry; 13 are open to participants now.
Seung-Jung Park has 2 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
4 of the studies in Myocardial Infarction with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT03412435Seung-Jung ParkAsan Medical Center Myocardial Infarction Registry | 2026-12-31 |
| NCT04755387Dong-A UniversityTicagrelor De-escalation Strategy in AMI Patients | 2027-01-15 |
Among the 99 studies in Myocardial Infarction with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates long-term outcome of patients diagnosed as acute myocardial infarction and treated with medication, coronary artery bypass surgery and percutaneous coronary intervention in Asan medical center, Korea.
This study will collect 3000 cases retrospectively and 2000 cases prospectively.
All consecutive acute myocardial infarction patients diagnosed through coronary angiography
Inclusion Criteria:
diagnosed as acute myocardial infarction and treated with medical treatment, coronary artery bypass surgery and percutaneous coronary intervention.
A composite event of all-cause death, non-fatal myocardial infarction and repeat revascularization
Time frame: 1 year
All cause death
Time frame: 5 year
Cardiac death
Time frame: 5 year
Myocardial infarction
Time frame: 5 year
A composite event of all-cause death and myocardial infarction
Time frame: 5 year
A composite event of cardiac death and myocardial infarction
Time frame: 5 year
Repeat revascularization
Time frame: 5 year
Stent thrombosis
according to Academic Research Consortium (ARC) criteria
Time frame: 5 year
Stroke
A stroke or cerebrovascular accident with loss of neurological function caused by an ischemic or hemorrhagic event with residual symptoms at least 24 hours after onset or leading to death.
Time frame: 5 year
Procedure success
Successful percutaneous coronary intervention at the intended target lesion with final instant residual stenosis of less than 30% by quantitative coronary angiography (QCA) and no event of death or Q wave myocardial infarction or urgent revascularization during hospitalization.
Time frame: 7 days
Surgery success
Successful surgery defines as no event of death or Q wave myocardial infarction or urgent revascularization during hospitalization.
Time frame: 7 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2018 (actual). Primary completion is estimated for Dec 2026, 104 months after the start.
Of 296 non-industry observational studies under Myocardial Infarction, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 140. This study's planned 104 months is above that.
Counting every sponsor, half of 333 studies reached it within 48 months; a quarter within 17 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seung-Jung Park